

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2022-23/14 May 13, 2022

To, Listing/ Compliance Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 To,

Listing/ Compliance Department National Stock Exchange of India Limited, "Exchange Plaza", Plot No C/1, G Block, Bandra Kurla Complex,

BSE CODE - 524348

Dear Sir / Madam,

Sub:Annual Disclosure under SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

Bandra (E), Mumbai 400 051

NSE SYMBOL: AARTIDRUGS

We would like to inform you that our Company is not falling under category of "Large Corporate" for the year ended March 31, 2022 as per the applicability criteria mentioned under the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 with respect to fundraising by issuance of Debt Securities by Large Corporates. Further, we are enclosing herewith **Annexure-B2** as required under the aforesaid circular. Kindly take the same on record.

Please take note of the above on your record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKÉSH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M.No.: A54527





Annexure B2

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

- 1. Name of the Company: Aarti Drugs Limited
- 2. CIN: L37060MH1984PLC055433
- 3. Report filed for FY: 2022
- 4. Details of the Current block (all figures in Rs crore): NA

S.No.	Particulars	Details
i.	2-year block period (Specify financial years)	2022, 2023
ii.	Incremental borrowing done in FY (T) (a)	NIL
III.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	NIL
iv.	Actual borrowing done through debt securities in FY (T) (c)	NIL
V.	Shortfall in the borrowing through debt securities, if any, for FY (T -1) carried forward to FY (T) (d)	NIL
vi.	Quantum of (d), which has been met from (c) (e)	NIL
vii.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T - 1) which was carried forward to FY (T)} (f)= (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	NIL





Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Manufacturers of : Bulk Drugs & Chemicals

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

S.No.	Particulars	Details
i.	2-year Block period (Specify financial years)	2021, 2022
ii.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}	NIL

Thanking you,

Yours faithfully,

For Aarti Drugs Limited

Rushikesh Deole Company Secretary & Compliance Officer Contact Details:- 022-24048200

Date: May 13, 2022



Adhish P. Patil Chief Financial Officer Contact Details:- 022-24048200